DALLAS, Dec. 19, 2012 /PRNewswire/ -- X-Change Corp (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is cannabis and hemp based extracts targeting Medical Cannabis, Cosmeceutical and Neutroceuticals and Social Usage solutions through multiple Phytiva Brand Product Lines. The Company issues a stronger outlook for 2013 based on new Phytiva Product Lines for the Medical Cannabis Industry as a whole. These new Phytiva Product Lines will be launched with Cannabis based formulations through Medical Cannabis dispensaries, Cannabis laboratories, and individual legal State grow operations on a State by State approved basis.
The Company is working with approved partners operating in legal jurisdictions under State approved permits developing its newest Cannabis based Phytiva Product lines that have identified over a dozen ailments that we believe that our products will be the superior choice on the market. These ailments include cancer, arthritis, influenza, HIV/ AIDS, PTSD and many more.
The global markets that the Phytiva product lines are targeting is enormous. The Cancer industry is estimated at $300 billion globally by 2025, the HIV Therapeutics market is estimated to be $21.8 Billion by 2018. This is in addition to the PTSD Therapeutics market which was worth $1.3 Billion in 2011. Recently, a cure for Cancer, if realized, is estimated to be worth over $ 1 trillion. Social use has just become available in Washington State and Oregon, many numbers are reported very high, but the Company is awaiting official word.
X-Change Corporation through its Phytiva Brand Product line intends to release product formulations that include high-level CBD's and variations of THC, CBD's, and other cannabinoid elements. These formulations will be in addition to the existing development of the hemp extract based products forthcoming in 2013.